FindMyKOL
Clinical trialNCT00333307SuspendedPhase 1Interventional

Evaluation of the Safety of Relaxin in Preeclampsia

SponsorCorthera, Inc.(formerly BAS Medical, Inc.), a member of the Novartis group of companiesEnrollment18Pre-Eclampsia
View the registry record on ClinicalTrials.gov

Summary

The lay summary the sponsor registered on ClinicalTrials.gov.

The purpose of this study is to determine whether different doses of recombinant human relaxin is safe when given to women with severe preeclampsia

Investigators

The overall officials registered on this study. Names that resolve to a FindMyKOL profile link to it; the rest are shown as registered.

  • Sam Teichman, MD

    Corthera, Inc.(formerly BAS Medical, Inc.), a member of the Novartis group of companies

    Study Director

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

2 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

United States
  • Central Baptist Hospital

    Lexington, Kentucky, United States

  • University of Cincinnati

    Cincinnati, Ohio, United States

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.

Recombinant human relaxin
Linked drugs open the directory filtered to KOLs working with them.clinicaltrials.gov ↗

Registration & key dates

Registry attributes as recorded on the ClinicalTrials.gov study record.

Start
31 Oct 2006
Primary completion
—
Completion
—
Last update posted
16 Mar 2010
Registered enrollment
18
Registry id
NCT00333307

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 24 Aug 2026. Registry facts are shown as registered by the study sponsor; FindMyKOL does not interpret them.